v3.26.1
Consolidated statements of changes in equity - EUR (€)
€ in Millions
Total
Attributable to equity holders of Sanofi
Share capital
Additional paid-in capital
Treasury shares
Reserves and retained earnings
Stock options and other share-based payments
Other comprehensive income
Attributable to non-controlling interests
Beginning balance at Dec. 31, 2024 € 77,857 € 77,507 € 2,526 € 0 € (840) € 68,185 € 5,260 € 2,376 € 350
Other comprehensive income for the period (4,774) (4,736)       243   (4,979) (38)
Net income for the period 5,837 5,812       5,812     25
Comprehensive income 1,063 1,076       6,055   (4,979) (13)
Dividend paid out of earnings (4,772) (4,772)       (4,772)      
Payment of dividends to non-controlling interests (32)               (32)
Share repurchase program [1] (3,988) (3,988)     (3,988)        
Reduction in share capital 0 0 (74)   3,868 (3,794)      
Tax on share cancellations [2] (15) (15)     (15)        
Share-based payment plans:                  
Exercise of stock options 15 15 1 14          
Issuance of restricted shares and vesting of existing restricted shares 0 0 3 (3)          
Value of services obtained from employees 177 177         177    
Tax effects of share-based payments (7) (7)         (7)    
Other changes arising from issuance of restricted shares [3] 15 15       15      
Other changes in non-controlling interests [4] (34)               (34)
Ending balance at Jun. 30, 2025 € 70,279 70,008 2,456 11 (975) 65,689 5,430 (2,603) 271
Share-based payment plans:                  
Dividend paid per share (in euros per share) € 3.92                
Other comprehensive income for the period € 84 89       (71)   160 (5)
Net income for the period 2,014 2,001       2,001     13
Comprehensive income 2,098 2,090       1,930   160 8
Payment of dividends to non-controlling interests (12)               (12)
Share repurchase program [1] (1,027) (1,027)     (1,027)        
Reduction in share capital 0 0 (22) (170) 934 (742)      
Tax on share cancellations [2] (4) (4)     (4)        
Exercise of stock options 0                
Issuance of restricted shares and vesting of existing restricted shares 0                
Employee share ownership plan 165 165 5 160          
Value of services obtained from employees 142 142         142    
Tax effects of share-based payments 0                
Other changes in non-controlling interests [4] 68               68
Ending balance at Dec. 31, 2025 71,710 71,376 2,439 1 (1,072) 66,877 5,572 (2,441) 334
Other comprehensive income for the period 1,617 1,605       290   1,315 12
Net income for the period 1,997 1,957       1,957     40
Comprehensive income 3,614 3,562       2,247   1,315 52
Dividend paid out of earnings (4,923) (4,923)       (4,923)      
Payment of dividends to non-controlling interests (26)               (26)
Share repurchase program [1] (1,003) (1,003)     (1,003)        
Reduction in share capital [1] 0 0 (15)   596 (581)      
Tax on share cancellations [2] (3) (3)     (3)        
Share-based payment plans:                  
Exercise of stock options 3 3   3          
Issuance of restricted shares and vesting of existing restricted shares [1] 0 0 4 (4) 102 (102)      
Value of services obtained from employees 184 184         184    
Tax effects of share-based payments 1 1         1    
Other changes arising from issuance of restricted shares [3] 10 10       10      
Ending balance at Jun. 30, 2026 € 69,567 € 69,207 € 2,428 € 0 € (1,380) € 63,528 € 5,757 € (1,126) € 360
Share-based payment plans:                  
Dividend paid per share (in euros per share) € 4.12                
[1] See Note B.8.2 and B.8.3. (for amounts relating to 2025, see Note D.15.4. to the consolidated financial statements for the year ended December 31, 2025).
[2] Reflects new regulations implemented on the taxation of share cancellations in Article 95 of the French Finance Bill for 2025.
[3] This line comprises the impact of the issuance of restricted shares to former employees of Opella subsequent to the date on which Sanofi lost control of Opella.
[4] This line mainly comprises changes in non-controlling interests arising from divestments and acquisitions.